**
In a race against time, health officials in the Democratic Republic of the Congo (DRC) have initiated a groundbreaking trial to combat the escalating Ebola outbreak in the Ituri region. Just six weeks after the World Health Organization (WHO) declared the outbreak a public health emergency on 17 May, the first patients are being enrolled in a treatment study that aims to test two experimental drugs against the deadly Bundibugyo strain of the virus. With confirmed cases climbing to 1,792 and 625 fatalities reported as of 9 July, the urgency for effective treatments has never been more palpable.
Swift Response to a Deadly Outbreak
The rapid establishment of the treatment trial, named Partners, represents a significant achievement in the face of a relentless health crisis. Scientists have expressed optimism that the swift enrolment of patients could lead to a breakthrough in reducing mortality rates associated with the Bundibugyo strain of Ebola, which claims roughly one in three lives. In Bunia, the capital of Ituri province, local residents are feeling the financial strain of the outbreak, with many voicing their hopes for the trial’s swift progress.
“I hope these drug trials proceed quickly,” said Neema Haba, a local mother and banana seller. “Financially, we are being driven to the brink by this outbreak, and nothing is going right. We are struggling to provide for our children.” The palpable sense of desperation underscores the human cost of this outbreak, as families grapple with the harsh realities of illness and loss.
The Human Toll and Challenges Faced
As the virus continues to spread, the response teams face significant hurdles. Despite efforts to trace approximately 75% of known contacts, community mistrust coupled with a highly mobile population hampers containment efforts. Additionally, some frontline workers have walked off the job, protesting unpaid wages. “At one point, we narrowly escaped being lynched,” recounted Ovide Maliabo, a driver for a burial team. “It’s a shame that we aren’t being financially supported.”
The dangers of working in such an environment cannot be overstated. Bahati John, the leader of a burial team, described his ordeal, stating, “I lost a tooth after being attacked by local people. We haven’t seen a single penny since we started working.” The lack of essential resources, from protective gear to vehicles for transporting victims, further complicates the already perilous task of managing the outbreak.
Promising Drugs on the Horizon
The Partners trial is set to evaluate two potential treatments: remdesivir, an antiviral developed by Gilead Sciences, and MBP134, a monoclonal antibody created by Mapp Biopharmaceutical. These drugs are administered intravenously, with MBP134 requiring a single infusion while remdesivir necessitates a ten-day course of treatment. Preliminary studies indicate that both medications have demonstrated efficacy against the Bundibugyo virus in animal models, raising hopes for improved outcomes among human patients.
Prof Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp highlights the trial’s goal: “What we want to see is if they indeed can lower mortality.” While Bundibugyo typically has a lower death rate than the more infamous Zaire strain, the stakes remain high, necessitating rigorous testing to determine the true potential of these medications.
A Collaborative Effort
The WHO has confirmed that sufficient quantities of both drugs have been secured for up to 1,200 patients, courtesy of donations from Gilead and the US government. This collaboration marks a pivotal moment in the fight against Ebola, as researchers aim to recruit between 700 and 1,000 participants for the trial. The ability to include patients of all ages, including pregnant and breastfeeding women, is a significant step towards comprehensive treatment strategies.
Prof Amanda Rojek, an international principal investigator for the Partners trial, emphasised the importance of swift action in response to the outbreak. “It’s just fantastic we’ve managed to get started so quickly,” she said, noting the lessons learned from previous Ebola crises that delayed clinical trials for over a year. The current focus is on maintaining simplicity in the trial’s design to expedite the process and maximise patient enrolment.
Why it Matters
The ongoing Ebola outbreak in the DRC is a stark reminder of the fragility of public health systems in the face of infectious disease. With the stakes as high as they are, the success of this trial could not only lead to effective treatments but also restore faith in health authorities and improve community engagement. As the world watches, the outcomes of these trials may redefine the response to Ebola outbreaks, potentially saving countless lives in the process.